In the last trading session, 2.09 million Aldeyra Therapeutics Inc (NASDAQ:ALDX) shares changed hands as the company’s beta touched 1.30. With the company’s per share price at $2.85 changed hands at $0.36 or 14.46% during last session, the market valuation stood at $167.64M. ALDX’s last price was a discount, traded about -320.0% off its 52-week high of $11.97. The share price had its 52-week low at $1.42, which suggests the last value was 50.18% up since then. When we look at Aldeyra Therapeutics Inc’s average trading volume, we note the 10-day average is 1.78 million shares, with the 3-month average coming to 2.45 million.
Analysts gave the Aldeyra Therapeutics Inc (ALDX) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.29. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ALDX as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Aldeyra Therapeutics Inc’s EPS for the current quarter is expected to be -$0.19.
Aldeyra Therapeutics Inc (NASDAQ:ALDX) trade information
Instantly ALDX was in green as seen at the end of in last trading. With action 24.73%, the performance over the past five days has been green. The jump to weekly highs of 2.93 on Friday, 11/17/23 added 14.46% to the stock’s daily price. The company’s shares are showing year-to-date downside of -59.05%, with the 5-day performance at 24.73% in the green. However, in the 30-day time frame, Aldeyra Therapeutics Inc (NASDAQ:ALDX) is 71.69% up. Looking at the short shares, we see there were 3.35 million shares sold at short interest cover period of 1.55 days.
The consensus price target for the stock as assigned by Wall Street analysts is $9.83, meaning bulls need an upside of 71.01% from its current market value. According to analyst projections, ALDX’s forecast low is $7.00 with $15.00 as the target high. To hit the forecast high, the stock’s price needs a -426.32% plunge from its current level, while the stock would need to soar -145.61% for it to hit the projected low.
Aldeyra Therapeutics Inc (ALDX) estimates and forecasts
Data shows that the Aldeyra Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -71.07% over the past 6 months, a 19.81% in annual growth rate that is considerably higher than the industry average of 11.30%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Aldeyra Therapeutics Inc will rise 13.60%, while the growth in revenue is estimated to hit -18.50% for the next quarter.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $330k.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 5.38%. The 2023 estimates are for Aldeyra Therapeutics Inc earnings to increase by 21.36%.
Aldeyra Therapeutics Inc is expected to release its next quarterly earnings report on November 03.
Aldeyra Therapeutics Inc (NASDAQ:ALDX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.02% of Aldeyra Therapeutics Inc shares while 60.74% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 61.99%. There are 60.74% institutions holding the Aldeyra Therapeutics Inc stock share, with Perceptive Advisors Llc the top institutional holder. As of Sep 29, 2023, the company held 19.30% of the shares, roughly 11.35 million ALDX shares worth $32.35 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 5.73% or 3.37 million shares worth $9.61 million as of Sep 29, 2023.
Among Mutual Funds, the top two as of Sep 29, 2023 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. With 2.13 million shares estimated at $6.08 million under it, the former controlled 3.63% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.88% of the shares, roughly 1.7 million shares worth around $4.84 million.